Join Growin Stock Community!

Neurosense therapeutics ltd.NRSNW.US Overview

US StockHealthcare
(No presentation for NRSNW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NRSNW AI Insights

NRSNW Overall Performance

NRSNW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NRSNW Recent Performance

-

Neurosense therapeutics ltd.

0.05%

Avg of Sector

-0.31%

S&P500

NRSNW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NRSNW Key Information

NRSNW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NRSNW Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Price of NRSNW

NRSNW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NRSNW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NRSNW's latest earnings report released?

    The most recent financial report for Neurosense therapeutics ltd. (NRSNW) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NRSNW's short-term business performance and financial health. For the latest updates on NRSNW's earnings releases, visit this page regularly.

  • How much cash does NRSNW have?

    At the end of the period, Neurosense therapeutics ltd. (NRSNW) held Total Cash and Cash Equivalents of 666K, accounting for 0.4 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NRSNW's EPS continuing to grow?

    According to the past four quarterly reports, Neurosense therapeutics ltd. (NRSNW)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of NRSNW?

    The latest valuation data shows Neurosense therapeutics ltd. (NRSNW) has a Price-To-Earnings (PE) ratio of -3.2 and a Price/Earnings-To-Growth (PEG) ratio of 0.22. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.